Short answer. For KPV, the policy describes enforcement discretion for the acetate, in topical and oral dosage forms [2]. An injection is not in that sentence. KPV is still not FDA-approved. As of Oct 29, 2026.

What Appendix B identifies

KPV acetate is printed as molecular formula C16H30N4O4·CH3COOH, molecular weight 402.5 g/mol, sequence H-Lys-Pro-Val-OH as the acetate [2]. Three amino acids. The policy says the free base and the acetate were both discussed in Category 2 until April 22, 2026, and that this did not change 503A status. CDER recommended against listing either form. The advisory committee voted in favor of inclusion [2].

The discretion sentence is narrower than "KPV" as a nickname. It says discretion for KPV acetate is appropriate for topical and oral dosage forms compounded from an ingredient with a certificate of analysis that meets the policy [2].

Oral still has an extra condition

If a peptide is compounded as an oral dosage form, the policy expects the compounder to keep documentation that the specific formulation achieves adequate oral bioavailability in people [2]. That is a record about that formula. It is not a dose, and it is not a result you should expect.

HHS says its reasons include documented single-ingredient use, lot testing that reports the active piece by mass spectrometry plus endotoxin and microbial results, and the absence of an observed safety signal rather than a full safety file [2]. Absence of a file is not proof of safety. The July briefing, as the KPV evidence page still explains, did not find human evidence adequate for the proposed uses. The Oct 28 policy does not erase that briefing. It describes enforcement discretion under conditions [1][2].

A topical nomination was never evidence that an injection works. That was true before Oct 28. The new policy still does not name an injectable route for KPV acetate [2].

Sommar Club does not prescribe or sell KPV.

FAQ

Can a clinic point at this policy and offer KPV injections? The discretion sentence we read names topical and oral acetate forms [2]. Ask them to show the sentence that names an injection. If they cannot, the policy they are citing does not describe that product.

Is KPV on the 503A bulks list now? No. The notice says that list is still in rulemaking [1].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, Appendix B, KPV, and condition 8. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.